<DOC>
	<DOCNO>NCT02472210</DOCNO>
	<brief_summary>Most Parkinsonism related pain assign one five category : musculoskeletal pain , neuritic radicular pain , dystonia associate pain , primary central pain , akathitic discomfort . In PD pain tends affect side body initially , severe affect motor symptom . Botulinum toxins effective treatment modality grow number neurological condition . They study variety condition associate PD include dystonia , jaw tremor , apraxia eyelid opening , camptocormia , dyskinesia , freeze gait , sialhorrea , overactive bladder constipation . There study use Botulinum Toxin pain PD . The investigator perform double-blind , randomize cross-over study evaluate efficacy safety individual pattern BTXA injection target painful muscle vs. placebo injection .</brief_summary>
	<brief_title>The Use Botox Advanced Parkinson 's Patients Experiencing Pain</brief_title>
	<detailed_description>The investigator perform double-blind , randomize cross-over study evaluate efficacy safety individual pattern BTXA injection target painful muscle vs. placebo injection . Primary outcome measure global pain perceive participant . To assess endpoint investigator use:1. change pain Numeric Rating Scale ( NRS ) telephone BTXA placebo injection 4 week post injection 2.change Visual Analogue Scale ( Edmonton Symptom Assessment System : Numerical Scale ) study visit . Secondary outcome percentage responder , Physician rat Clinical Global Impression ( CGI ) , Unified Parkinson Disease Rating Scale ( MDS-UPDRS ) medication , quality life Parkinson Disease Questionnaire ( PDQ-39 ) adverse event assess study visit .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Subjects advance PD ( Hoehn Yahr 35 ) painful limbs respond antiparkinsonian agent sufficiently . BTXA treatment na√Éve patient receive within last 12 month ( include indication ) . Stable PD pain medication least 30 day Competence selfreport pain severity Visual Analogue Scale ( VAS ) Subjects primary cause pain unrelated PD associate another medical condition e.g . severe arthritis Subjects severity refractory pain unfixed analgesic schedule Subjects unable self report pain severity VAS Subjects undergo acute infection acute intercurrences . Any contraindication receive BTXA injection : 1 . Subjects hypersensitive BTXA ingredient formulation component container ( Clostridium Botulinum toxin type A neurotoxin complex 900 kD , Human Serum Albumin Sodium Chloride ) . 2 . The presence infection propose injection site ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>